KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clover Health Investments (CLOV) Cash & Equivalents (2019 - 2025)

Clover Health Investments' Cash & Equivalents history spans 7 years, with the latest figure at $78.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 59.75% year-over-year to $78.3 million; the TTM value through Dec 2025 reached $78.3 million, down 59.75%, while the annual FY2025 figure was $78.3 million, 59.75% down from the prior year.
  • Cash & Equivalents reached $78.3 million in Q4 2025 per CLOV's latest filing, down from $190.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $485.7 million in Q2 2021 to a low of $78.3 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $247.9 million, with a median of $231.5 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: surged 159483.42% in 2021, then crashed 65.4% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $300.0 million in 2021, then plummeted by 65.4% to $103.8 million in 2022, then rose by 18.38% to $122.9 million in 2023, then surged by 58.34% to $194.5 million in 2024, then crashed by 59.75% to $78.3 million in 2025.
  • Per Business Quant, the three most recent readings for CLOV's Cash & Equivalents are $78.3 million (Q4 2025), $190.1 million (Q3 2025), and $188.6 million (Q2 2025).